Neurology/CNS Phase 3 Deal Benchmarks — US Only

Understanding Neurology/CNS Deal Benchmarks at Phase 3

Phase 3 Neurology/CNS licensing deals in US Only territory command a median upfront payment of $283M, with values ranging from $172M at the low end to $421M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.0B to $1.9B, with a median of $1.4B. Royalty rates for neurology/cns assets at this stage typically fall between 11.8% and 18.1% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.